Home
October 2009 November 2009 December 2009
Su Mo Tu We Th Fr Sa
Week 45 1 2 3 4 5 6 7
Week 46 8 9 10 11 12 13 14
Week 47 15 16 17 18 19 20 21
Week 48 22 23 24 25 26 27 28
Week 49 29 30
Reach urologists

Pharmacological Effects of Saw Palmetto Extract in the Lower Urinary Tract - Abstract Show Comments PDF Print E-mail
  
Friday, 27 March 2009

Department of Pharmacokinetics and Pharmacodynamics, Pharmacognosy and Global Center of Excellence Program, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.

Saw palmetto extract (SPE), an extract from the ripe berries of the American dwarf palm, has been widely used as a therapeutic remedy for urinary dysfunction due to benign prostatic hyperplasia (BPH) in Europe. Numerous mechanisms of action have been proposed for SPE, including the inhibition of 5alpha-reductase. Today, alpha(1)-adrenoceptor antagonists and muscarinic cholinoceptor antagonists are commonly used in the treatment of men with voiding symptoms secondary to BPH. The improvement of voiding symptoms in patients taking SPE may arise from its binding to pharmacologically relevant receptors in the lower urinary tract, such as alpha(1)-adrenoceptors, muscarinic cholinoceptors, 1,4-dihyropyridine receptors and vanilloid receptors. Furthermore, oral administration of SPE has been shown to attenuate the up-regulation of alpha(1)-adrenoceptors in the rat prostate induced by testosterone. Thus, SPE at clinically relevant doses may exert a direct effect on the pharmacological receptors in the lower urinary tract, thereby improving urinary dysfunction in patients with BPH and an overactive bladder. SPE does not have interactions with co-administered drugs or serious adverse events in blood biochemical parameters, suggestive of its relative safety, even with long-term intake. Clinical trials (placebo-controlled and active-controlled trials) of SPE conducted in men with BPH were also reviewed. This review should contribute to the understanding of the pharmacological effects of SPE in the treatment of patients with BPH and associated lower urinary tract symptoms (LUTS).

Written by:
Suzuki M, Ito Y, Fujino T, Abe M, Umegaki K, Onoue S, Noguchi H, Yamada S.   Are you the author?

Reference:
Acta Pharmacol Sin. 2009 Mar;30(3):227-81.
doi:10.1038/aps.2009.1

PubMed Abstract
PMID:19262550

UroToday.com BPH and Male LUTS Section

 

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 2
PoorBest


 
Visitor Ratings:
Healthcare Professionals:
4 (1 votes)

No Affiliation:
1 (1 votes)


Bookmark and Share

Member's Section

Login

Sign Up

Quick Search

Meet the Expert


All Experts


Featured Conference

Media and Publisher

Advertising Rates
Reprints

Working with Industry

Case Studies
Sponsorship Opportunities

BPH and Male LUTS
Sponsored By